← 返回

转移性结直肠癌中 PD-L1 表达与 CD8 淋巴细胞浸润的异质性及其预后意义

英文原题:Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance.

查看英文原题

Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance.

PubMed 2023/01/16(内容时间) Heliyon

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

在转移性结直肠癌中,原发肿瘤与配对转移灶之间存在 PD-L1 表达和 CD8 TIL 浸润的异质性。

中文摘要

近年来,免疫检查点抑制剂已成为转移性结直肠癌(mCRC)的重要治疗手段。越来越多证据表明,肿瘤微环境中存在TIL(肿瘤浸润淋巴细胞),是PD-1/PD-L1阻断疗法发挥作用的前提。本研究旨在比较原发肿瘤及配对转移灶中的PD-L1表达,以及分化簇4(CD4)和CD8 TIL浸润情况。

共纳入111例在本院接受手术的mCRC患者。采用组织芯片免疫组织化学检测PD-L1、CD4和CD8表达。以综合阳性评分(CPS)评估PD-L1表达,评分≥1定义为阳性。阳性染色TIL面积占比≥10%定义为“高”,<10%定义为“低”。

35/111例(31.5%)患者的原发肿瘤和配对转移灶之间PD-L1表达不一致(κ=0.137,P=0.142)。这种异质性与原发肿瘤和配对转移灶之间CD8 TIL浸润不一致显著相关(P=0.003)。与对应的结直肠癌原发肿瘤相比,肺转移灶CD8 TIL浸润更多(P=0.022;中位数8.5%比5.0%),而肝转移灶CD8 TIL浸润更少(P=0.028;中位数3.0%比5.0%)。肺转移灶中CD4⁺和CD8⁺ TIL浸润面积占比均高于肝转移灶(P=0.005,中位数15.0%比9.0%;P=0.001,中位数8.5%比3.0%)。与错配修复功能正常(pMMR;MSI-L/MS-S)亚组相比,错配修复缺陷(dMMR;MSI-H)组原发肿瘤的CD8 TIL浸润面积占比,以及配对转移灶的CD4、CD8 TIL浸润面积占比均更高(P=0.026,中位数15.0%比5.0%;P=0.039,中位数15.0%比9.0%;P=0.015,中位数15.0%比5.0%)。术前化疗/放疗可能增加原发肿瘤中的CD8 TIL浸润(P=0.045;中位数10.0%比5.0%)。原发肿瘤中的CD8 TIL浸润是总生存期的独立预测因素(HR=0.28,95% CI 0.09–0.93,P=0.038)。

mCRC原发肿瘤与配对转移灶之间存在PD-L1表达和CD8 TIL浸润异质性。原发肿瘤中的CD8 TIL浸润可独立预测mCRC患者总生存期。

展开英文摘要原文

In recent years, immune checkpoint inhibitors have become a major therapeutic method for the treatment of metastatic colorectal cancer (mCRC). Growing evidence indicates that tumour-infiltrating lymphocytes (TILs) in the tumour microenvironment are a prerequisite for the effectiveness of PD-1/PD-L1 blockade therapy. In this study, we aimed to compare PD-L1 expression and cluster of differentiation 4 (CD4) and CD8 TIL infiltration in primary tumours and paired metastases.

Altogether, 111 patients with mCRC who underwent surgery at our hospital were included. PD-L1, CD4, and CD8 expression were detected by immunohistochemistry in a tissue microarray. PD-L1 expression was assessed using the combined positivity score (CPS), and a score 1 was judged as positive. The area proportion of TILs with positive staining 10% was classified as "high", while <10% was classified as "low".

We observed the discordance of PD-L1 expression between primary tumours and paired metastases in 35/111 (31.5%) patients ( = 0.137, P = 0.142). This heterogeneity was significantly correlated with discordance of CD8 TIL infiltration between primary tumours and paired metastases (P = 0.003). Compared with corresponding colorectal cancer tumours, lung metastases showed more CD8 TIL infiltration (P = 0.022, median: 8.5% vs. 5.0%), whereas liver metastases exhibited less CD8 TIL infiltration (P = 0.028, median: 3.0% vs. 5.0%). Area proportion of CD4 + and CD8 + TIL infiltration in lung metastases were all higher than those in liver metastases (P = 0.005, median: 15.0% vs. 9.0%; P = 0.001, median: 8.5% vs. 3.0%). Compared with p MMR (MSI-L/MS-S) subgroup, area proportion of CD8 TIL infiltration in primary tumours and CD4, CD8 TIL infiltration in paired metastases were all higher in d MMR (MSI-H) group (P = 0.026, median: 15.0% vs 5.0%; P = 0.039, median: 15.0% vs 9.0%; P = 0.015, median: 15.0% vs 5.0%). Preoperative chemo/radiotherapy may increase CD8 TIL infiltration in primary tumours (P = 0.045, median: 10.0% vs. 5.0%). CD8 TIL infiltration in primary tumours was an independent predictive factor for overall survival (HR 0.28, 95% CI 0.09-0.93, P = 0.038).

Heterogeneity in PD-L1 expression and CD8 TIL infiltration was found between primary tumours and paired metastases in mCRC. CD8 TIL infiltration in primary tumours could independently forecast the overall survival of patients with mCRC.

论文信息

作者
Xin H、Zhou C、Wang G、Liu Y、Zhang J、Liu Y、Li B、Zhang J
第一作者单位
Department of General Surgery, Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, Hebei, People's Republic of China.China
通讯作者单位
Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.China
期刊
Heliyon2023 Feb
原文标识
PubMed 36814622 · DOI 10.1016/j.heliyon.2023.e13048